Prospective Asian Multicenter Prostate Cancer Focal Therapy Study (ProAMFocal)

Last updated: July 5, 2024
Sponsor: Singapore General Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Urologic Cancer

Prostate Cancer

Prostate Disorders

Treatment

Focal Therapy for Prostate Cancer

Clinical Study ID

NCT06491056
CIRB 2023/2055
  • Ages 40-85
  • Male

Study Summary

This is a multicenter observational study of patients undergoing focal therapy for prostate cancer in Asia

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Prostate Adenocarcinoma

  • Maximum Gleason score 4+4

  • Maximum cancer volume 1.5 ml (up to 2 lesions) or 3 ml (single lesion)

  • Maximum Prostate Specific Antigen (PSA) level 15 ng/dl

  • Maximum clinical stage T2c

  • American Society of Anesthesiologist Criteria 2 or less

Exclusion

Exclusion Criteria:

  • Extra-prostatic Extension on multi parametric magnetic resonance imaging (mpMRI);capsular contact is permitted

Study Design

Total Participants: 500
Treatment Group(s): 1
Primary Treatment: Focal Therapy for Prostate Cancer
Phase:
Study Start date:
May 06, 2023
Estimated Completion Date:
May 06, 2048

Study Description

Patients undergoing Focal Cryotherapy, Focal HIFU, Focal IRE, Focal Laser ablation, or other partial gland ablation modalities for prostate cancer will be recruited.

Connect with a study center

  • Singapore General Hospital

    Singapore, 169856
    Singapore

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.